Dr. Lee S. Cohen, Director of the Women’s Mental Health Center at Massachusetts General Hospital, recently shared his ideas to optimize the likelihood of treatment for postpartum depression Ob.Gyn News on August 27, 2024.
I have written in my first two columns of 2024 about how obstacles for women having access to perinatal mental health care are not well understood. This is despite the almost uniform adoption of post-PPD depression practices (PPD) over the last 10-15 years in the United States, the approval and use of effective pharmacological and non-pharmacological therapies for PPD and the increasing number of perinatal access programs in various states and hospitals.
I want to review this issue because I believe that it is extremely important to better understand the obstacles that patients face after childbirth so that we can level the curve to perinatal cataracts. It turns out that the test is easy, but access to care for those who have a positive screen with significant symptoms of depression is a completely distinct result.
Recently, a group of researchers examiner Obstacles to detecting and treating women for PPD. In a meta-analysis that included 32 reviews, the researchers analyzed the obstacles that women face when seeking help, access to care and participate in treatment for mental health problems while pregnant or during the postpartum period. Researchers have found that women have a wide variety of obstacles for searching and accessing social, political, organizational, interpersonal, professional health care and individual factors at each level of care. Overall, the researchers have categorized the obstacles into six general issues and 62 cases and I would like to point out some of the biggest contributors below.
In meta-analysis, an important rate to decide to consult a health care professional was the lack of understanding of what was a perinatal mental illness. This lack of understanding led women to ignore or minimize their symptoms. Others said that the cost of traveling or the organization of children’s care were factors that prevented them from making an appointment with a provider. Some women reported that normalizing their symptoms by their health professionals was an obstacle to the early stages of Care Street and others were unclear for the role that a health care professional played in the involvement of social services and the removal of their child from their child.
One of the most important social factors identified in the study is the PPD -related stigma. It is unfortunate that for so many postpartum patients, an excellent PPD -related mark still remains despite the efforts of a large number of interested parties, including the scientific community, the defense groups and the celebrities that have released publicly and describe their experiences with PPD. For so many patients after childbirth, there is a failure to leave the mark, shame, humility and isolation associated with the suffering with PPD.
Another factor identified in the study as an obstacle to care was the lack of a network to help patients with childbirth tour the changing roles associated with the new parental responsibility, which is magnified if a patient has developed a significant depressive disorder. That is why a strong social support network is crucial to help women navigate the innovation of the new mom. We knew this as a field almost 30 years ago when Michael W. O’Hara, Phd, published a paper in the General psychiatry Noting that social support was an important predictor for the risk of PPD.
When we talk to patients in the clinic and even when we interviewed our upcoming documentary More than bluewhich will be completed in the fall of 2024, women in the postpartum period reported the navigation of today’s healthcare system as one of the biggest obstacles to care. It was suffered by PPD and delivered a book of potential providers, without anyone who helps navigate this referral system, really asks a new mom to climb a very high mountain. In addition, mothers living in rural areas probably do not have the type of perinatal mental health services that women make in more urban areas.
It is becoming more and more clear that it is not the lack of availability of effective treatments that are the problem. As I mentioned in previous columns, over the last 15 years they have given us much greater understanding of the effectiveness of antidepressants as well as non -pharmacological psychotherapy for women who may not want to be in medicine. We now have very effective psychotherapy and there is enthusiasm for other new treatments that may have a role in the treatment of post -childbirth depression, including the use of neurosteroids, ketamine or esketamine and psychedelic or neurotranslations such as transnational magnetic stimulation. There is also no lack of well -thought -out treatments and new and effective therapies that, as we move towards reproductive psychiatric precision, may be useful in adapting patient treatment.
If we want to understand the anatomy of the cataract of perinatal treatment, the systematic evaluation of these barriers can lead us to a course to understand how to build the bridge in well -being after childbirth for the suffering women. While what is on the horizon is very exciting, we have not yet encountered these obstacles that prevent women from accessing this extension of the series of therapeutic options. This is, in fact, the challenge for patients, their families, defense groups, political organizations and society in general. Bridging this gap is a weight that we all share as we try to alleviate the pain associated with such an extremely healing disease, while access to treatment still feels beyond the approach of so many after childbirth.
As we continue our research on new treatments, we need to keep in mind that they will have no value unless we understand how to facilitate access to these treatments for the largest number of patients. This effort really emphasizes the importance of research science and the implementation of health services and that we must work early and often with colleagues if we really want to achieve this goal.
Dr. Cohen is director of the Ammonium-Pinizotto Mental Health Center at Massachusetts General Hospital (MGH) in Boston, which provides information resources and conducts clinical care and research in reproductive mental health. He is a consultant to the manufacturers of psychiatric drugs. The steps for PPD are funded by the Marriott Foundation. Complete notification information for Dr. Cohen is available at Womensmentalhealth.org. Email to Dr. Cohen at obnews@mDedge.com.
